Remove 2020 Remove Packaging Remove Pharmaceutical Companies
article thumbnail

Rising Demand for Pharmaceutical Secondary Packaging Providers

Roots Analysis

This continuously growing pipeline of pharmaceutical drug products has inadvertently led to an increase in the demand for their associated primary packaging and Secondary Packaging solutions. . 3] Some of the advantages offered by pharmaceutical secondary packaging have been depicted below.

article thumbnail

Ireland is open: The biologics boom boosting the Irish economy

pharmaphorum

With an attractive corporate tax rate and the youngest workforce in the EU, Ireland continues to be a popular destination for life science companies to settle. Although cities such as Dublin and Cork were the traditional centres for pharmaceutical companies, a new wave of regional investment is happening across the country.

Packaging 124
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).

article thumbnail

Halting Europe’s essential medicines manufacturing exodus

European Pharmaceutical Review

Between 2000 and 2020, Asian companies outperformed European companies for new approvals of CEPs, increasing their number CEPs from 183 to 2,369. This left pharmaceutical companies in Europe with no European API supply source, and only a few suppliers in Asia.

article thumbnail

CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024

Pharmaceutical Technology

Both modalities have emerged as the most used platform technologies in developing oligonucleotide-based drugs for CNS disorders since 2020. ASOs accounted for more than half ($3.54 billion), while siRNAs made up more than a third ($2.51 billion) of these deals. Give your business an edge with our leading industry insights.

article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).

article thumbnail

Evorel patches incl. Evorel Conti Alternative drugs

Druggist

Theramex bought Evorel range of products from Janssen Pharmaceutical Companies (Johnson & Johnson) in October 2019. Theramex committed to increase manufacturing of Evorel products by investing in an additional manufacturer and additional packaging equipment. Stocks should come back in the second half of 2020.